NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that significant scientific data on ERBITUX® (cetuximab) will be presented at the American Society of Clinical Oncology (ASCO) 2008 Annual Meeting taking place May 30 through June 3, 2008 in Chicago. In total, ImClone and its partners Bristol-Myers Squibb Company and Merck KGaA plan to present over 80 oral presentations, poster discussions and abstracts featuring new clinical data on ERBITUX. Additionally, new clinical development data on novel antibodies in ImClone’s proprietary pipeline will be highlighted at the ASCO meeting.
